Related Experiment Video
Updated: May 19, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes
Jennifer A Namazy1, Vanessa E Murphy, Heather Powell
1Dept of Allergy–Immunology, Scripps Clinic, San Diego, CA 92108, USA. janamazy@mac.com
Insights
Maternal asthma exacerbations and corticosteroid use increase risks for low birth weight and preterm delivery. Moderate-to-severe asthma during pregnancy is linked to small for gestational age and low birth weight infants.
Area of Science:
- Obstetrics and Gynecology
- Pulmonology
- Neonatology
Background:
- Asthma is a common chronic respiratory condition affecting women of reproductive age.
- Poorly controlled asthma during pregnancy can lead to adverse maternal and fetal outcomes.
- The specific impact of asthma exacerbations, corticosteroid use, and severity on perinatal outcomes requires further clarification.
Purpose of the Study:
- To systematically review and meta-analyze the association between maternal asthma exacerbations, oral corticosteroid use, asthma severity, and prematurity and intrauterine growth restriction.
- To quantify the risks of specific perinatal outcomes in relation to maternal asthma control.
Main Methods:
- Systematic review and meta-analysis of cohort studies published between 1975 and March 2012.
- Inclusion of nine studies reporting perinatal outcomes (low birth weight, preterm birth, small for gestational age) stratified by maternal asthma status.
- Statistical analysis using relative risks (RR) and 95% confidence intervals (CI).
Main Results:
- Maternal asthma exacerbations were significantly associated with low birth weight (RR 3.02) and preterm delivery (RR 1.54).
- Oral corticosteroid use in asthmatic mothers was linked to low birth weight (RR 1.41) and preterm delivery (RR 1.51).
- Moderate-to-severe maternal asthma increased the risk of small for gestational age (RR 1.24) and low birth weight (RR 1.15) infants.
Conclusions:
- Asthma exacerbations, oral corticosteroid use, and moderate-to-severe asthma during pregnancy are associated with adverse perinatal outcomes.
- These outcomes include preterm delivery, low birth weight, and small for gestational age infants.
- Further research is needed to understand the effect of maternal asthma control on perinatal health.
Abstract:
This systematic review and meta-analysis sought to investigate whether asthma exacerbations, oral corticosteroid use or asthma severity are associated with prematurity and intrauterine growth restriction. Cohort studies published between 1975 and March 11, 2012 were considered for inclusion. 138 publications were identified for possible inclusion, and nine papers met the inclusion criteria, by reporting perinatal outcomes of interest (low birth weight, <2500 g), pre-term birth (<37 weeks gestation unless otherwise stated) and small for gestational age (<10th percentile for gestational age and sex) in groups of asthmatic patients stratified by history of exacerbations, oral corticosteroid use or asthma severity. Maternal asthma exacerbations and oral corticosteroid use had a significant effect on outcomes, including low birth weight (RR 3.02, 95% CI 1.87-4.89 and RR 1.41, 95% CI 1.04-1.93, respectively) and pre-term delivery (RR 1.54, 95% CI 0.89-2.69 and RR 1.51, 95% CI 1.15-1.98, respectively). Moderate-to-severe asthma during pregnancy was associated with an increased risk of small for gestational age (RR 1.24, 95% CI 1.15-1.35) and low birth weight (RR 1.15, 95% CI 1.05-1.26) infants. These data suggest that asthma exacerbations, oral corticosteroid use or asthma severity defined as moderate-to-severe may be associated with pre-term delivery, low birth weight, and small for gestational age infants. Further studies on the effect of maternal asthma control on perinatal outcomes are warranted.
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma I: Introduction
Asthma-I: Introduction
Asthma III: Clinical Manifestations